生活质量量表评价参附注射液对肺癌化疗患者生活质量的影响

摘要

目的 评价参附注射液对治疗肺癌的三种一线方案(泰素联合顺铂、长春瑞滨联合顺铂、吉西他滨联合顺铂)治疗非小细胞肺癌时患者生活质量的影响.方法 133例接受至少两周期化疗的非小细胞肺癌患者,随机分为先配合参附注射液组(67例)和后配合参附注射液组(66例).先配合参附注射液组第1化疗周期同时予参附注射液(配合参附组),第2化疗周期仅实施相对应的化疗方案(单纯化疗组)；后配合参附注射液组第1化疗周期仅实施化疗(单纯化疗组),第2化疗周期同时予参附注射液(配合参附组).应用两套国外常用的生活质量量表EORTC QLQ-C30和FLIC,通过随机自身前后交叉对照,观察参附注射液对患者生活质量的影响.结果 133例患者治疗后的生活质量均较治疗前有不同程度的改善,有显著差异(P＜0.01)；配合参附组较单纯化疗组生活质量改善更明显,有显著差异(P ＜0.05)；参附注射液对化疗所致的疲乏、恶心呕吐、腹泻等毒副反应具有一定的拮抗作用(P＜0.05).结论 参附注射液能改善非小细胞肺癌患者应用一线化疗方案治疗时的生活质量.%Objective To evaluate the influence of Shenfu Injection (SHF) on the quality of life of patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Methods A total of 133 patients with NSCLC receiving at least two cycles of chemotherapy with taxol plus cisplatin (TP)/vinorelbine plus cisplatin (NP) or gemcitabine plus cisplatin (GP) were randomized into SHF pre-treatment group (with SHF given only in the first cycle) and SHF post-treatment group (with SHF given only in the second cycle). The Quality of Life Questionnaire-Core 30 (QLQ-C30) and the Functional Living Index-Cancer (FLIC) were used to evaluate the quality of life of the patients after the treatments. Results Both of the groups showed improved quality of life after the treatments (P<0.01), but the improvements were more obvious in SHF pre-treatment group (P<0.05). SHF showed favorable effects in relieving such adverse effects as fatigue, nausea, vomiting and diarrhea associated with the chemotherapy. Conclusions SHF can improve the quality of life in NSCLC patients receiving chemotherapies.